This double-blind early phase II randomized placebo-controlled trial published in 2020, was conducted of benfotiamine with the objective of collecting preliminary data on feasibility, safety and efficacy in mild cognitive impairments, mild dementia experienced by Alzheimer’s patients (amyloid positive). Results suggest that benfotiamine offers a low cost, high safety intervention that can improve outcomes for delaying onset or severity of AD.
References:
Gibson, G. E., Luchsinger, J. A., Cirio, R., Chen, H., Franchino-Elder, J., Hirsch, J. A., Bettendorff, L., Chen, Z., Flowers, S. A., Gerber, L. M., Grandville, T., Schupf, N., Xu, H., Stern, Y., Habeck, C., Jordan, B., & Fonzetti, P. (2020). Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer’s disease : JAD, 78(3), 989–1010. https://doi.org/10.3233/JAD-200896
